Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
1.750
-0.140 (-7.41%)
At close: Dec 20, 2024, 4:00 PM
1.820
+0.070 (4.00%)
After-hours: Dec 20, 2024, 7:13 PM EST
Virax Biolabs Group Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
| Revenue | 0.08 | 0.16 | 0.01 | - | 0.12 | 0.1 |
| Revenue Growth (YoY) | 7.03% | 1727.11% | - | - | 23.97% | - |
| Cost of Revenue | 0.05 | 0.11 | 0.01 | - | 0.13 | 0.05 |
| Gross Profit | 0.03 | 0.05 | -0 | - | -0.01 | 0.05 |
| Selling, General & Admin | 4.63 | 4.59 | 3.55 | 1.3 | 0.51 | 0.61 |
| Research & Development | 1.68 | 1.56 | 2.18 | 0.43 | 0.12 | 0.09 |
| Operating Expenses | 6.31 | 6.16 | 5.73 | 1.73 | 0.64 | 0.7 |
| Operating Income | -6.28 | -6.11 | -5.73 | -1.73 | -0.64 | -0.65 |
| Interest Expense | -0.04 | -0.03 | -0.02 | -0.02 | -0.03 | -0.09 |
| Other Non Operating Income (Expenses) | -0.01 | -0.02 | -0 | -0 | 0 | 0 |
| EBT Excluding Unusual Items | -6.33 | -6.15 | -5.75 | -1.75 | -0.67 | -0.74 |
| Asset Writedown | -0.39 | -0.39 | - | - | - | - |
| Legal Settlements | -0.21 | -0.21 | - | - | - | - |
| Other Unusual Items | 0.21 | 0.01 | 0.29 | - | - | - |
| Pretax Income | -6.72 | -6.74 | -5.46 | -1.75 | -0.67 | -0.74 |
| Earnings From Continuing Operations | -6.58 | -6.74 | -5.46 | -1.75 | -0.67 | -0.74 |
| Minority Interest in Earnings | 0 | 0.01 | 0 | 0.04 | 0.02 | 0.03 |
| Net Income | -6.58 | -6.73 | -5.46 | -1.71 | -0.65 | -0.71 |
| Net Income to Common | -6.58 | -6.73 | -5.46 | -1.71 | -0.65 | -0.71 |
| Shares Outstanding (Basic) | 3 | 2 | 1 | 1 | 0 | 0 |
| Shares Outstanding (Diluted) | 3 | 2 | 1 | 1 | 0 | 0 |
| Shares Change (YoY) | 50.43% | 88.75% | 11.15% | 297.67% | 130.43% | - |
| EPS (Basic) | -2.46 | -3.36 | -5.13 | -1.79 | -2.71 | -6.81 |
| EPS (Diluted) | -2.47 | -3.36 | -5.13 | -1.79 | -2.71 | -6.81 |
| Free Cash Flow | -5.28 | -7.2 | -4.18 | -0.81 | -0.59 | -0.74 |
| Free Cash Flow Per Share | -1.98 | -3.59 | -3.93 | -0.85 | -2.45 | -7.13 |
| Gross Margin | 39.59% | 32.34% | -15.94% | - | -7.62% | 45.81% |
| Operating Margin | -7397.95% | -3903.69% | -66963.68% | - | -520.54% | -652.05% |
| Profit Margin | -7753.22% | -4304.81% | -63748.32% | - | -525.75% | -711.32% |
| Free Cash Flow Margin | -6220.66% | -4602.71% | -48823.35% | - | -476.65% | -745.54% |
| EBITDA | -6.12 | -6.05 | - | - | - | - |
| D&A For EBITDA | 0.16 | 0.05 | - | - | - | - |
| EBIT | -6.28 | -6.11 | -5.73 | -1.73 | -0.64 | -0.65 |
| Revenue as Reported | - | - | - | - | 0.12 | 0.1 |
Source: S&P Capital IQ. Standard template.
Financial Sources.